ArticleOphthalmology and therapy2023

Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan.

Yasuo Yanagi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.